http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102228441-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6cf9bf9153bb2851f3a5a5b81e127704
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192
filingDate 2011-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2013-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8eb9e82c941b937651eb7de2c2410dcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5e41925ddfc406ec6eb9f0c45a574f8
publicationDate 2013-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-102228441-B
titleOfInvention Dexibuprofen sustained-release pellet and preparation method thereof
abstract The invention discloses a dexibuprofen sustained-release pellet and a preparation method thereof. The dexibuprofen sustained-release pellet comprises a celphere, a drug layer and an external coating. In the terms of the total weight of the pellet, the celphere accounts for 15 % to 30 %. The drug layer consists of dexibuprofen, a binding agent and talcum powder, wherein the dexibuprofen accounts for 70-85 %, the binding agent accounts for 1-10 %, and the talcum powder accounts for 0.1-3 %. The external coating consists of a coating material and the talcum powder, the coating material accounts for 0.5-3 % and the talcum powder accounts for 0.1-3 %. The invention further provides the preparation method of the dexibuprofen sustained-release pellet. In the invention, the dexibuprofen sustained-release pellet has the advantages of good stability, high bioavailability, good mobility and wide application prospect and is beneficial to subpackage of preparations or is further pressed in a form of a tablet.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103156855-A
priorityDate 2011-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494320
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13836
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502717
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6658
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527785
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID39912
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425654805
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5988
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3394
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407932856
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453030527
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID93091914
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4093
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323524

Total number of triples: 35.